Anemia Market to Grow at a Significant CAGR Across the 7MM Through 2036 | DelveInsight

DelveInsight's "Anemia Market Insights, Epidemiology, and Market Forecast - 2036" report delivers an in-depth understanding of the Anemia, historical and forecasted epidemiology and the Anemia market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Explore the intricate details of the Anemia Market Report @ https://www.delveinsight.com/report-store/anemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

Key Takeaways from Anemia Market Report
• In April 2026, Johnson & Johnson announced that the US FDA granted Priority Review to the supplemental Biologics License Application (sBLA) for nipocalimab (IMAAVY), confirming the urgent need for treatment options in wAIHA.
• In February 2026, Sanofi announced that rilzabrutinib was granted Breakthrough Therapy Designation (BTD) by the US FDA for the treatment of patients with wAIHA, and the Japanese Ministry of Health, Labour and Welfare provided rilzabrutinib an Orphan Designation (ODD) for the same condition.
• In February 2026, Ayrmid announced presentation of additional positive results for OMISIRGE in treating SAA at TANDEM 2026.
• Globally, an estimated 40% of children aged 6-59 months, 37% of pregnant women, and 30% of women aged 15-49 years are affected by anemia.
• Iron deficiency remains the leading cause of anemia globally, accounting for roughly half of all cases, and disproportionately affects women under the age of 50.
• Aplastic Anemia accounted for approximately 2,600 cases in the 7MM in 2025.
• Anemia prevalence was lowest in children ages 2-11 (approximately 5%) and highest in adults 60 and older (approximately 13%).
• Japan accounted for approximately 12 million cases of IDA in 2025.
• The Anemia market Companies include Ayrmid, Teva Pharmaceuticals, Agios Pharmaceuticals, Sanofi, Astellas, Johnson & Johnson, Cellenkos, and others.
• Promising Anemia Therapies include OMISIRGE, ALVAIZ, AQVESME/PYRUKYND, Rilzabrutinib, IMAAVY, Roxadustat, CK0801, and others.

Get a Free sample for the Anemia Market Forecast, Size & Share Analysis Report @ https://www.delveinsight.com/sample-request/anemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

What is Anemia?
Anemia is a condition marked by a lower-than-normal number of red blood cells or haemoglobin, reducing the blood's ability to carry oxygen to tissues. It disproportionately affects women and children and, in severe cases, can impair cognitive and motor development in children and lead to complications for pregnant women and their babies. The condition arises from multiple factors, including poor nutrition, infections, chronic diseases, heavy menstrual bleeding, pregnancy-related issues, and genetic predisposition, though iron deficiency remains the most common cause. Diagnosis is confirmed mainly through a complete blood count (CBC), which measures hemoglobin, red blood cell count, and hematocrit, with additional tests such as iron studies, vitamin B12 and folate levels, and reticulocyte count used to determine the underlying cause.

Anemia Epidemiology Segmentation in the 7MM
• Total Prevalent Cases of Anemia
• Total Diagnosed Prevalent Cases of Anemia
• Type-specific Diagnosed Prevalent Cases of Anemia
• Gender-specific Diagnosed Prevalent Cases of Anemia
• Age-specific Diagnosed Prevalent Cases of Anemia
• Severity-specific Diagnosed Prevalent Cases of Anemia
• Total Treated Cases of Anemia

Download the report to understand which factors are driving Anemia epidemiology trends @ https://www.delveinsight.com/report-store/anemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

Anemia Approved Therapies
• Omidubicel (OMISIRGE): Ayrmid (Gamida Cell)
Omidubicel is the first HSCT therapy for patients with severe aplastic anemia (SAA), indicated for adults and children aged six years and older who lack a compatible stem cell donor and undergo reduced-intensity conditioning. It was approved by the US FDA in December 2025. Omidubicel addresses the limitations of umbilical cord blood (UCB) as a source, including delayed hematopoietic recovery and increased infections, and provides additional graft options for patients with SAA who need HSCT.

• Eltrombopag choline (ALVAIZ): Teva Pharmaceuticals
Eltrombopag choline is an oral thrombopoietin (TPO) receptor agonist that works to increase platelet production by interacting with the transmembrane domain of the human TPO-receptor to initiate signaling cascades that induce proliferation and differentiation of megakaryocytes. In November 2023, the US FDA approved ALVAIZ for the treatment of certain forms of thrombocytopenia and SAA, covering ITP, Thrombocytopenia with Hep C, and SAA.

Anemia Pipeline Analysis
• Rilzabrutinib (WAYRILZ): Sanofi
Rilzabrutinib is the first BTK inhibitor for immune thrombocytopenia (ITP), helping address the root cause of disease through multi-immune modulation. It is approved in the US for adults with persistent or chronic ITP who have had an insufficient response to a previous treatment, and is currently being studied across additional rare diseases including wAIHA, IgG4-RD, and SCD; these additional indications remain investigational.

• CK0801: Cellenkos
CK0801 is a first-in-class, allogeneic, cord blood-derived T-regulatory cell product developed from Cellenkos' proprietary manufacturing platform, which overcomes immune dysfunction by inhibiting key drivers of inflammation. CK0801 contains robust regulatory T-cells derived from healthy donor cord blood units and is currently undergoing evaluation in a Phase I clinical trial.

Anemia Companies
Ayrmid, Teva Pharmaceuticals, Agios Pharmaceuticals, Sanofi, Astellas, Johnson & Johnson, Cellenkos, and others

Discover more about therapies set to grab major Anemia market share @ https://www.delveinsight.com/sample-request/anemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

Anemia Market Outlook
The anemia therapeutics market has evolved from supportive care to innovation-driven treatments targeting disease mechanisms. Early management relied on iron supplements, transfusions, and erythropoiesis-stimulating agents, while improved intravenous iron formulations expanded options despite pricing pressures. Recent advances include HIF-PH inhibitors, erythroid maturation agents, and emerging gene and cell therapies. The Iron Deficiency Anemia market is expected to exceed USD 2 billion across the 7MM by 2036, whereas the aplastic anemia market is projected to decline after 2026 due to generic PROMACTA entry.

Scope of the Anemia Market Report
• Study Period: 2022-2036
• Forecast Period: 2026-2036
• Coverage: 7MM
• Anemia Companies: Ayrmid, Teva Pharmaceuticals, Agios Pharmaceuticals, Sanofi, Astellas, Johnson & Johnson, Cellenkos, and others
• Anemia Therapies: OMISIRGE, ALVAIZ, AQVESME/PYRUKYND, Rilzabrutinib, IMAAVY, Roxadustat, CK0801, and others
• Anemia Therapeutic Assessment: Anemia current marketed and emerging therapies
• Anemia Market Dynamics: Anemia market drivers and market barriers
• Competitive Intelligence Analysis: SWOT analysis, Conjoint Analysis, Market entry strategies
• Anemia Unmet Needs, KOL's views, Analyst's views, Anemia Market Access and Reimbursement

To know more about Anemia companies working in the treatment market, visit @ https://www.delveinsight.com/sample-request/anemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

Table of Contents
1. Key Insights
2. Report Introduction
3. Executive Summary of Anemia
4. Key Events
5. Epidemiology and Market Forecast Methodology of Anemia
6. Anemia Market Overview at a Glance
7. Disease Background and Overview of Anemia
8. Guidelines for Anemia
9. Epidemiology and Patient Population of Anemia
10. Patient Journey of Anemia
11. Marketed Therapies of Anemia
12. Emerging Drugs of Anemia
13. Anemia: 7MM Analysis
14. Unmet Needs of Anemia
15. SWOT Analysis of Anemia
16. KOL Views of Anemia
17. Market Access and Reimbursement of Anemia
18. Appendix
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Company Name: DelveInsight Business Research LLP
Contact Person: Abhishek kumar
Email: info@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com

About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

This release was published on openPR.